Deal count is running a bit lower than 2016 and 2015, which saw closer to 500 deals. But 2017 was a year of mega-deals, with the third quarter alone bringing in several $100 million+ rounds. Now six top venture capitalists in biotech, including Wende Hutton of Canaan Partners, reflect on what might happen in 2018.